Literature DB >> 27343012

Cereblon in health and disease.

Hyoung Kyu Kim1,2, Tae Hee Ko1, Bayalagmaa Nyamaa1, Sung Ryul Lee1,2, Nari Kim1, Kyung Soo Ko1, Byoung Doo Rhee1, Chul-Seung Park3, Bernd Nilius4, Jin Han5.   

Abstract

Cereblon (CRBN) is a substrate receptor of the E3 ubiquitin ligase complex that has been linked to autosomal recessive non-syndromic mental retardation. Several key findings suggest diverse roles of CRBN, including its regulation of the large-conductance calcium- and voltage-activated potassium (BKCa) channels, regulation of thalidomide-binding proteins, and mediation of lenalidomide treatment in multiple myeloma. Recent studies also indicate that CRBN is involved in energy metabolism and negatively regulates AMP-activated protein kinase signaling. Mice with genetic depletion of CRBN are resistant to various stress conditions including a high-fat diet, endoplasmic reticulum stress, ischemia/reperfusion injury, and alcohol-related liver damage. In this review, we discuss the various roles of CRBN in human health and disease and suggest avenues for further research to enhance our basic knowledge and clinical application of CRBN.

Entities:  

Keywords:  AMPK; BKCa; Cereblon; E3 ligase complex; Immunomodulatory drugs; Mental retardation

Mesh:

Substances:

Year:  2016        PMID: 27343012     DOI: 10.1007/s00424-016-1854-1

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  82 in total

1.  Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Gremlin.

Authors:  J Capdevila; T Tsukui; C Rodríquez Esteban; V Zappavigna; J C Izpisúa Belmonte
Journal:  Mol Cell       Date:  1999-11       Impact factor: 17.970

2.  Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel.

Authors:  Sandile E J Williams; Phillippa Wootton; Helen S Mason; Jonathan Bould; David E Iles; Daniela Riccardi; Chris Peers; Paul J Kemp
Journal:  Science       Date:  2004-11-04       Impact factor: 47.728

3.  A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation.

Authors:  Joseph J Higgins; Joanna Pucilowska; Roni Q Lombardi; John P Rooney
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

4.  Glutamine, glutamine synthetase and Huntington's disease.

Authors:  C J Carter
Journal:  Lancet       Date:  1981-06-27       Impact factor: 79.321

Review 5.  Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Authors:  Farrukh T Awan; Amy J Johnson; Rosa Lapalombella; Weihong Hu; Margaret Lucas; Beth Fischer; John C Byrd
Journal:  Leuk Lymphoma       Date:  2010-01

6.  Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation.

Authors:  Joseph J Higgins; Jin Hao; Barry E Kosofsky; Anjali M Rajadhyaksha
Journal:  Neurogenetics       Date:  2008-04-15       Impact factor: 2.660

7.  Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Authors:  Rebekka K Schneider; Vera Ademà; Dirk Heckl; Marcus Järås; Mar Mallo; Allegra M Lord; Lisa P Chu; Marie E McConkey; Rafael Kramann; Ann Mullally; Rafael Bejar; Francesc Solé; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2014-09-18       Impact factor: 31.743

8.  High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

Authors:  Daniel Heintel; Alberto Rocci; Heinz Ludwig; Arnold Bolomsky; Simona Caltagirone; Martin Schreder; Sabine Pfeifer; Heinz Gisslinger; Niklas Zojer; Ulrich Jäger; Antonio Palumbo
Journal:  Br J Haematol       Date:  2013-04-09       Impact factor: 6.998

9.  The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels.

Authors:  Yi-An Chen; Yi-Jheng Peng; Meng-Chun Hu; Jing-Jia Huang; Yun-Chia Chien; June-Tai Wu; Tsung-Yu Chen; Chih-Yung Tang
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

10.  Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Chung-Wu Lin; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Yao-Chang Chen; Hsiao-Yun Lu; Hsin-An Hou; Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Sheng-Je Chou; Hwei-Fang Tien
Journal:  Ann Hematol       Date:  2014-04-01       Impact factor: 3.673

View more
  10 in total

1.  Crystal structure of XCC3289 from Xanthomonas campestris: homology with the N-terminal substrate-binding domain of Lon peptidase.

Authors:  Rahul Singh; Sonali Deshmukh; Ashwani Kumar; Venuka Durani Goyal; Ravindra D Makde
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-09-16       Impact factor: 1.056

2.  Ohgata, the Single Drosophila Ortholog of Human Cereblon, Regulates Insulin Signaling-dependent Organismic Growth.

Authors:  Satoru Wakabayashi; Naoya Sawamura; André Voelzmann; Meike Broemer; Toru Asahi; Michael Hoch
Journal:  J Biol Chem       Date:  2016-10-04       Impact factor: 5.157

Review 3.  Cereblon: promise and challenges for combating human diseases.

Authors:  Hyoung Kyu Kim; Jung Eun Seol; Sang Woo Ahn; Seungje Jeon; Chul-Seung Park; Jin Han
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 3.657

Review 4.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 5.  Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives.

Authors:  Ilaria Saltarella; Concetta Altamura; Aurelia Lamanuzzi; Benedetta Apollonio; Angelo Vacca; Maria Antonia Frassanito; Jean-François Desaphy
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

6.  Rescue of Learning and Memory Deficits in the Human Nonsyndromic Intellectual Disability Cereblon Knock-Out Mouse Model by Targeting the AMP-Activated Protein Kinase-mTORC1 Translational Pathway.

Authors:  Charlotte C Bavley; Richard C Rice; Delaney K Fischer; Amanda K Fakira; Maureen Byrne; Maria Kosovsky; Bryant K Rizzo; Dolores Del Prete; Armin Alaedini; Jose A Morón; Joseph J Higgins; Luciano D'Adamio; Anjali M Rajadhyaksha
Journal:  J Neurosci       Date:  2018-02-19       Impact factor: 6.167

7.  BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice.

Authors:  Tae-Yong Choi; Seung-Hyun Lee; Soo-Jeong Kim; Youhwa Jo; Chul-Seung Park; Se-Young Choi
Journal:  Sci Rep       Date:  2018-12-05       Impact factor: 4.379

8.  Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.

Authors:  Shaunna L Beedie; Phoebe A Huang; Emily M Harris; Jonathan D Strope; Christopher Mahony; Cindy H Chau; Neil Vargesson; William D Figg
Journal:  FASEB J       Date:  2020-07-17       Impact factor: 5.834

Review 9.  Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.

Authors:  Qinglin Shi; Lijuan Chen
Journal:  J Immunol Res       Date:  2017-08-15       Impact factor: 4.818

10.  CRBN Is a Negative Regulator of Bactericidal Activity and Autophagy Activation Through Inhibiting the Ubiquitination of ECSIT and BECN1.

Authors:  Mi-Jeong Kim; Yoon Min; Jae-Hyuck Shim; Eunyoung Chun; Ki-Young Lee
Journal:  Front Immunol       Date:  2019-09-18       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.